Will Kindred Biosciences, Inc. (KIN) Run Out of Steam Soon?

June 14, 2018 - By Vivian Currie

Kindred Biosciences, Inc. (NASDAQ:KIN) Logo

Investors sentiment decreased to 0.78 in 2018 Q1. Its down 0.15, from 0.93 in 2017Q4. It turned negative, as 6 investors sold Kindred Biosciences, Inc. shares while 21 reduced holdings. 9 funds opened positions while 12 raised stakes. 16.83 million shares or 3.46% less from 17.44 million shares in 2017Q4 were reported.
The New York-based Renaissance Limited Liability has invested 0.01% in Kindred Biosciences, Inc. (NASDAQ:KIN). Goldman Sachs accumulated 14,492 shares. Bancshares Of America De holds 0% or 22,600 shares in its portfolio. Barclays Public Limited Com reported 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN). Evanson Asset Limited Liability reported 0.03% stake. 50,000 are owned by Nj State Employees Deferred Compensation Plan. 1,119 were accumulated by Tower Research Ltd Co (Trc). C M Bidwell Assocs reported 0.07% in Kindred Biosciences, Inc. (NASDAQ:KIN). Citigroup reported 0% stake. Northern Tru Corporation owns 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 265,617 shares. Moreover, Comml Bank Of New York Mellon Corporation has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 88,163 shares. Dimensional Fund Ltd Partnership holds 1.37M shares. State Of Wisconsin Investment Board has 15,000 shares for 0% of their portfolio. Connor Clark Lunn Limited owns 75,775 shares. Federated Inc Pa reported 2,314 shares or 0% of all its holdings.

Since January 2, 2018, it had 0 insider purchases, and 9 sales for $1.04 million activity. On Thursday, March 15 the insider Townsend Raymond sold $25,232.

The stock of Kindred Biosciences, Inc. (NASDAQ:KIN) hit a new 52-week high and has $11.86 target or 4.00 % above today’s $11.40 share price. The 9 months bullish chart indicates low risk for the $321.52M company. The 1-year high was reported on Jun, 14 by Barchart.com. If the $11.86 price target is reached, the company will be worth $12.86M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 5.07% or $0.55 during the last trading session, reaching $11.4. About 78,452 shares traded. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 39.72% since June 14, 2017 and is uptrending. It has outperformed by 27.15% the S&P500.

Analysts await Kindred Biosciences, Inc. (NASDAQ:KIN) to report earnings on August, 6. They expect $-0.38 EPS, down 31.03 % or $0.09 from last year’s $-0.29 per share. After $-0.36 actual EPS reported by Kindred Biosciences, Inc. for the previous quarter, Wall Street now forecasts 5.56 % negative EPS growth.

Kindred Biosciences, Inc. (NASDAQ:KIN) Ratings Coverage

Among 3 analysts covering Kindred Biosciences (NASDAQ:KIN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Kindred Biosciences had 4 analyst reports since December 27, 2017 according to SRatingsIntel. The stock of Kindred Biosciences, Inc. (NASDAQ:KIN) earned “Buy” rating by H.C. Wainwright on Friday, March 2. H.C. Wainwright maintained the shares of KIN in report on Wednesday, May 9 with “Buy” rating. The firm earned “Buy” rating on Monday, February 26 by FBR Capital. The firm earned “Hold” rating on Wednesday, December 27 by C.L. King.

More recent Kindred Biosciences, Inc. (NASDAQ:KIN) news were published by: Seekingalpha.com which released: “KindredBio announces positive results from KIND-014 for the treatment of gastric ulcers in horses” on May 30, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO” on June 01, 2018. Prnewswire.com‘s news article titled: “Kindred Biosciences to Present at Jefferies 2018 Global Healthcare Conference and 8th Annual LD Micro Invitational …” with publication date: May 29, 2018 was also an interesting one.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $321.52 million. The companyÂ’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Kindred Biosciences, Inc. (NASDAQ:KIN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: